Hydroxylation at C-3′ of doxorubicin alters the selected phenotype of cellular drug resistance

✍ Scribed by Leonard Lothstein; Trevor W. Sweatman; Waldemar Priebe

• Publisher: Elsevier Science
• Year: 1995
• Tongue: English
• Weight: 272 KB
• Volume: 5
• Category: Article
• ISSN: 0960-894X
• DOI: 10.1016/0960-894x(95)00300-i

✦ Synopsis

Hydroxylation at C-3' of doxorubicin (DOX) yields the uncharged congener hydroxyrubicin, which circumvents P-glycoprotein-mediated drug resistance without loss of topoisomerase II inhibitory activity. Hydroxyrubicin-resistant cells exhibit a phenotype that is uniquely different from DOX resistance by expressing non-functional P-glycoprotein and hypersensitivity to anti-mitotic drugs.